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P neumocystis pneumonia (PCP) due to Pneumocystis jirovecii (P. jirovecii) infection is the 
leading cause of fatal opportunistic infections in immu-
nocompromised patients [1-5].  PCP in patients with 
rheumatic disease has a different clinical course from 
that in patients with acquired immunodeficiency syn-
drome (AIDS),  with a mortality rate as high as 32-50% 
[6 , 7].  In patients with systemic rheumatic disease,  the 
overall incidence of PCP is around 2%; however,  
higher patient age,  lower lymphocyte count,  coexisting 
pulmonary disease,  the use of moderate to high doses 
of glucocorticoids,  and concomitant immunosuppres-
sive agents increase the risk of PCP [8-11].  The specific 
underlying rheumatic disease affects the morbidity rate:  
8-12% in granulomatosis with polyangiitis,  6.5% in 
polyarteritis nodosa,  2.7% in polymyositis/dermato-
myositis,  2% in systemic lupus erythematosus,  and 
0.1-0.3% in rheumatoid arthritis [12].
Sulfamethoxazole-trimethoprim (SMX/TMP) has 
been reported to be effective in preventing PCP in 
patients with rheumatic disease,  resulting in a lower 
incidence of PCP [13].  The prevention rate has been 
reported to be 89-100% in HIV-positive patients [14-16] 
and 91% (95% confidence interval [CI],  68-98%) in 
HIV-negative patients [17].
However,  clinicians often have to discontinue SMX/
TMP due to adverse events (AEs),  e.g.,  skin rash,  
increased serum creatinine,  elevation of liver enzymes,  
hypoglycemia,  hyperpotassemia,  and hyponatremia 
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Pneumocystis pneumonia (PCP) due to Pneumocystis jirovecii infection is the leading cause of fatal opportunis-
tic infections in immunocompromised patients.  We will determine whether a daily sulfamethoxazole-tri-
methoprim (SMX/TMP) dose of 200/40 mg was non-inferior to 400/80 mg for PCP prevention in patients with 
systemic rheumatic disease under immunosuppressive therapy.  This is a randomized,  open-label,  multicenter 
controlled trial.  The primary outcome is the rate of PCP prevention at 52 weeks.  The secondary outcome is the 
discontinuation rate of SMX/TMP.  The trial will evaluate the optimal dose of SMX/TMP for PCP prevention in 
patients with systemic rheumatic disease under immunosuppressive therapy.
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[18-20].  The frequency of AEs due to SMX/TMP in 
rheumatic disease patients is higher than in the general 
population,  with a discontinuation rate of 36.4-38.5% 
[21].  It is important to reduce the discontinuation rate 
of PCP prophylaxis,  because most patients with sys-
temic rheumatic disease require long-term immuno-
suppressive therapy.
Utsunomiya et al.  [22] conducted a multicenter,  
open-label,  randomized controlled trial to compare the 
effectiveness and discontinuation rates among three 
groups: a single-strength group (SMX/TMP at 
400/80 mg daily),  a half-strength group (200/40 mg 
daily),  and an escalation group (starting with 40/8 mg 
daily,  increasing incrementally to 200/40 mg daily).  
They reported that both the half-strength group and the 
escalation group had an excellent estimated non-inci-
dence rate of PCP,  and both groups showed superior 
safety compared to the single-strength group.  However,  
they also reported that there were no PCP cases in any 
group at week 24.
Against this background,  we designed a trial to 
demonstrate the non-inferiority of the half-dose pro-
phylaxis group by comparing a conventional therapy 
group (SMX/TMP at 400/80 mg daily) with a half-dose 
prevention group (SMX/TMP at 200/40 mg daily).  The 
primary endpoint was the non-incidence rate of PCP,  
and the major secondary endpoint was the drug contin-
uation rate at week 52.
Endpoints
Primary outcome measure. The primary out-
come measure will be the number of patients in each 
treatment arm who are diagnosed with PCP.  The diag-
nosis of PCP will be considered definitive if P. jirovecii is 
identified by a microscopic analysis of respiratory sam-
ples from patients who meet each of the following three 
criteria: clinical manifestations (pyrexia,  dry cough,  or 
dyspnea),  hypoxemia,  and radiologic findings compat-
ible with PCP.  The diagnosis of PCP will be considered 
presumptive if a patient meets all three of the afore-
mentioned criteria and has either a positive polymerase 
chain reaction for P. jirovecii deoxyribonucleic acid or an 
increased serum level of β-D glucan with an appropri-
ate response to standard treatments for PCP [23].
Secondary outcome measures. The secondary 
outcome measures are (1) the drug discontinuation rate 
in each treatment arm for any reason,  and (2) the AEs 
due to SMX/TMP at week 52.
Eligibility Criteria
The target population will be patients admitted to 
our 2 hospitals (see below) who fulfill the classification 
criteria for their respective systemic rheumatic diseases.
Inclusion criteria. (1) Men and women aged 
over 20 years.  (2) Admission to one of our hospitals for 
the diagnosis and/or treatment of new-onset or relapsed 
systemic rheumatic disease during the period from 
April 1,  2018,  to March 31,  2021.  (3) Current treat-
ment with ≥ 0.6 mg/kg/day of oral prednisolone or an 
equivalent dose of one or more corticosteroids with or 
without any immunosuppressant.  (4) No prior treat-
ment with SMX/TMP,  pentamidine isethionate,  dap-
sone,  or atovaquone.  (5) Serum creatinine levels within 
the hospital’s normal range.  (6) Able and willing to 
provide written informed consent.
Exclusion criteria. (1) Contraindications to 
SMX/TMP.  (2) Past history of PCP.  (3) Prior treatment 
with a biologic agent.  (4) Currently uncontrollable 
complication(s).  (5) Body weight < 40 kg.  (6) Currently 
pregnant or breastfeeding.  (7) Unable to begin SMX/
TMP within 14 days of starting prednisolone.  (8) 
Unable to provide informed consent.
Methods
Aim and design. This is a 52-week,  randomized,  
open-label,  two-arm,  parallel-group,  multicenter con-
trolled trial.  It is a pragmatic clinical trial designed to 
identify the optimal dose of SMX/TMP for the prophy-
laxis of PCP in patients with systemic rheumatic dis-
ease.  Fig. 1 provides the study flow chart.
Our trial hypothesis is that at week 52,  SMX/TMP at 
a daily dose of 200/40 mg will result in a lower drug 
discontinuation rate and a PCP prevention rate that is 
similar to that of SMX/TMP at a daily dose of 
400/80 mg.
Setting. This trial will be conducted in two hos-
pitals: Juntendo University Hospital and the Juntendo 
Tokyo Koto Geriatric Medical Center in Tokyo,  Japan.
Ethical considerations and registration. This 
study will be conducted in accordance with the 
Declaration of Helsinki and the Ethics Guidelines for 
Clinical Research issued by the Ministry of Health,  
Labour,  and Welfare of Japan.  Informed consent will be 
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obtained from all patients before registration.  The trial 
has been approved by the Ethics Committees of both 
institutions involved in the study,  and has been 
reviewed and ethically approved by the Ethics 
Committee of Juntendo University Hospital (#17-237).  
The study was registered at the University Hospital 
Medical Information Network (UMIN) Clinical Trial 
Registry as UMIN000031513.
Withdrawal of participants. Participants will 
have the right to withdraw from this study at any time 
for any reason.
Randomization. Three hundred patients will be 
recruited from the two hospitals,  and then randomly 
allocated in a 1 : 1 ratio (using an online database) to a 
conventional prevention therapy group or a half-dose 
prevention therapy group with block randomization.  
Patients will be randomized automatically on the day of 
website registration.
AEs and safety. AEs e.g.,  skin rash,  increased 
serum creatinine,  elevation of liver enzymes,  hypogly-
cemia,  hyperpotassemia,  and hyponatremia,  will be 
recorded as part of the data collection for each session 
and will be reported to the clinical authorities and to the 
Ethics Committee.  Participants suffering from AEs will 
be referred for appropriate treatment.
Routine clinical practice. All other clinical pro-
cedures (including the use and tapering of glucocorti-
coids,  the use of any immunosuppressant without bio-
logical agents,  and blood examinations) will be 
performed according to the routine practice of each 
institution and independently of trial-arm allocation.  
In particular,  the frequency with which blood examina-
tions and chest X-rays are monitored will be based on 
existing protocols and clinician preferences.
Statistical Considerations
Sample size. Three hundred patients are to be 
recruited from the two centers and randomly allocated 
in a 1 : 1 ratio.  As this is a non-inferiority trial,  the 
sample size calculation is based on a baseline PCP inci-
dence of 91% [17],  a clinically relevant non-inferiority 
margin of 10%,  a one-sided alpha of 2.5% (equivalent 
to a two-sided alpha of 5%),  and < 10% protocol viola-
tions.  Due to this anticipated protocol violation rate,  a 
greater number of patients will be recruited to the full 
study,  as not all patients will be included in the final 
analysis.
Outcome analysis. The outcome measure of this 
trial will be defined in terms of the numbers of recruited 
and randomized patients,  the protocol fidelity,  and the 
follow-up rates by trial arm.  These statistics will inform 
a Consolidated Standards of Reporting Trials 
(CONSORT) diagram reporting the patient recruit-
ment,  treatment,  and retention.  All data will be coded 
for the patients’ privacy,  locked,  and stored in the study 
office.  The trial will be self-monitored at its initiation 
and at the end of the trial,  and at least once a year.
The patients’ baseline characteristics,  the treatment 
for underlying diseases and comorbidities,  and demo-
graphic factors will be summarized for each random-
ized group.  The multiple imputations method will be 
used to impute missing primary or secondary out-
comes.  To compare demographic and disease charac-
teristics between groups,  the Mann-Whitney U-test will 
be used for non-normally distributed variables.  
Categorical variables will be compared using Fisher’s 
exact test.  The drug discontinuation rates of each group 
will be compared with Kaplan-Meier curves that are 
plotted and evaluated using the log-rank test.
Discussion
This trial is intended to determine whether half-dose 
prevention therapy is non-inferior to conventional pre-
vention therapy with regard to the rate of PCP preven-
tion.  In this study,  we define the drug discontinuation 
rate as a secondary endpoint since 200/40 mg of SMX/
TMP was reported to result in a lower drug discontinu-
ation rate than 400/80 mg [22].  If the validity of our 
hypothesis is confirmed by the primary endpoint 
results,  half-dose prevention therapy may be estab-
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Fig. 1　 TMP/SMX: sulfamethoxazole-trimethoprim.
lished as optimal for the prophylaxis of PCP in patients 
with systemic rheumatic disease.
Systemic rheumatic diseases include not only those 
affecting young people,  such as  systemic lupus erythe-
matosus,  but also those affecting the elderly,  e.g.,  
microscopic polyangiitis and giant cell arteritis.  We 
reported the continuation rate of SMX/TMP in micro-
scopic polyangiitis patients at the Juntendo Tokyo Koto 
Geriatric Medical Center,  which is one of the facilities 
involved in the current trial [24].  Low drug tolerability 
in the elderly is a clinically significant problem,  and 
SMX/TMP is no exception in this regard.  We feel that 
these factors will reflect real-world practices as closely as 
possible.
This study may have no cases of PCP in either group 
during the observation period,  as in a previous study 
[22].  If the overall incidence of PCP is 0% in the cur-
rent trial,  the statistical analysis of the primary end-
point is not applicable.  In that case,  we will report 
whether 400/80 mg or 200/40 mg of SMX/TMP has a 
favorable preventive effect against PCP in patients with 
systemic rheumatic disease,  and we will evaluate the 
drug discontinuation rate as a secondary outcome.
In patients with systemic rheumatic disease,  PCP 
can be a fatal complication.  This is a clinically import-
ant trial as its ultimate goal is to achieve a decreased 
discontinuation rate of SMP/TMX without reducing the 
drug’s preventive effect.
Trial status. Issue date: February 28,  2018;  
Protocol original; Author Y.A.  At the time of manu-
script submission,  the trial was in the recruitment 
phase.
Recruitment. This trial is currently being estab-
lished.  Recruitment is scheduled to start at the first site 
by April 1,  2018.  The proposed start date is April 1,  
2018.  The proposed end date is March 31,  2022 (end of 
follow-up).
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